Drugs / MBS8(1V270)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04855435 | Apr 2021 → Mar 2027 expected | cutaneous melanoma, uveal melanoma | MonTa Biosciences ApS | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBS8(1V270) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04855435 ↗ |
| Action | Activate | “The investigational medicinal product is a TLR7 agonist” NCT04855435 ↗ |
| Route | Intravenous | “will be administered intravenously by infusion” NCT04855435 ↗ |
| Target | TLR7 | “The investigational medicinal product is a TLR7 agonist” NCT04855435 ↗ |